000156607 001__ 156607
000156607 005__ 20251017144634.0
000156607 0247_ $$2doi$$a10.3390/jcm14082615
000156607 0248_ $$2sideral$$a143868
000156607 037__ $$aART-2025-143868
000156607 041__ $$aeng
000156607 100__ $$0(orcid)0000-0002-6518-749X$$aIoakeim-Skoufa, Ignatios
000156607 245__ $$aCharting the Pathways of Cardiometabolic Multimorbidity: A Systematic Review of Clinical Trajectories
000156607 260__ $$c2025
000156607 5060_ $$aAccess copy available to the general public$$fUnrestricted
000156607 5203_ $$aBackground: Managing multimorbidity is a major challenge for healthcare systems. Cardiometabolic multimorbidity (CMM) is highly prevalent and linked to increased disease burden, functional decline, and mortality. While most studies focus on cross-sectional analyses, longitudinal approaches are essential for understanding disease progression and identifying patient groups who may benefit from targeted interventions. Objectives: This systematic review synthesises evidence from longitudinal studies on the incidence and progression of CMM, exploring transitions between multimorbidity clusters and their clinical implications. Methods: A systematic search was conducted in MEDLINE and EMBASE following PRISMA guidelines. Studies were included if they employed longitudinal designs and clustering techniques to assess multimorbidity evolution. The quality of evidence was evaluated using the GRADE system. Results: Ten studies met the inclusion criteria. CMM occurs across all age groups and both sexes, showing the highest mortality and functional decline rates. Patients with CMM frequently develop additional cardiometabolic conditions or transition to related clusters. Many also experience neurodegenerative and mental health disorders. Individuals from respiratory multimorbidity clusters often transition to CMM. Moreover, CMM is more prevalent in lower socioeconomic populations. Conclusions: Understanding multimorbidity trajectories enables targeted preventive strategies. Identifying patients with predictable progression can help design adequate and effective interventions, reduce health disparities, and improve healthcare outcomes.
000156607 536__ $$9info:eu-repo/grantAgreement/ES/DGA-FEDER/B01-20R$$9info:eu-repo/grantAgreement/ES/ISCIII/RD24-0005-0013$$9info:eu-repo/grantAgreement/ES/ISCIII-RICAPPS/RD21-0016-0019
000156607 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000156607 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000156607 700__ $$aLedesma-Calvo, Rubén
000156607 700__ $$aMoreno-Juste, Aida
000156607 700__ $$aRoque, Fátima
000156607 700__ $$aAtkins, Kerry
000156607 700__ $$aHernández-Rodríguez, Miguel Ángel
000156607 700__ $$aAza-Pascual-Salcedo, Mercedes
000156607 700__ $$aGonzález-Rubio, Francisca
000156607 700__ $$aLasala-Aza, Carmen
000156607 700__ $$aEsteban-Jiménez, Óscar
000156607 700__ $$0(orcid)0000-0003-2153-0417$$aAvedillo-Salas, Ana$$uUniversidad de Zaragoza
000156607 700__ $$aCebollada-Herrera, Celeste
000156607 700__ $$0(orcid)0000-0002-5440-1710$$aGimeno-Miguel, Antonio
000156607 700__ $$0(orcid)0000-0003-4629-6743$$aVicente-Romero, Jorge$$uUniversidad de Zaragoza
000156607 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000156607 773__ $$g14, 8 (2025), 2615 [15 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000156607 8564_ $$s534598$$uhttps://zaguan.unizar.es/record/156607/files/texto_completo.pdf$$yVersión publicada
000156607 8564_ $$s2804075$$uhttps://zaguan.unizar.es/record/156607/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000156607 909CO $$ooai:zaguan.unizar.es:156607$$particulos$$pdriver
000156607 951__ $$a2025-10-17-14:27:57
000156607 980__ $$aARTICLE